Apellis Pharmaceuticals

Yahoo Finance • 13 days ago

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS [https://www.chartmill.com/stock/quote/APLS]) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The biopharmaceutical company posted r... Full story

Yahoo Finance • 13 days ago

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGN Announced capped royalty purchase agreement with Sobi under which Apellis receives up to $300 million for 90... Full story

Yahoo Finance • 14 days ago

Apellis wins FDA label expansion for Empaveli in rare kidney disorders

[Headquarters of US Food and Drug Administration (FDA)] Grandbrothers/iStock Editorial via Getty Images Apellis Pharmaceuticals (NASDAQ:APLS [https://seekingalpha.com/symbol/APLS]) announced on Tuesday that the U.S. FDA approved its injec... Full story

Yahoo Finance • 15 days ago

Apellis Pharma Secures FDA Approval For EMPAVELI To Treat Rare Kidney Disorders

(RTTNews) - Apellis Pharmaceuticals Inc. (APLS) announced that the U.S. Food and Drug Administration has approved EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative g... Full story

Yahoo Finance • 15 days ago

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or primary IC-MPGN, and... Full story

Yahoo Finance • 20 days ago

Apellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial Results

WALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial results on Thursday, Jul... Full story

Yahoo Finance • 26 days ago

Interesting APLS Put And Call Options For September 19th

Investors in Apellis Pharmaceuticals Inc (Symbol: APLS) saw new options become available today, for the September 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the APLS options chain for the new... Full story

Yahoo Finance • 29 days ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

WALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific... Full story

Yahoo Finance • last month

Apellis stock holds Outperform rating at William Blair amid Izervay competition

Investing.com - William Blair has reiterated an Outperform rating on Apellis Pharmaceuticals (NASDAQ:APLS), a company currently valued at $2.41 billion with impressive revenue growth of 48% over the last twelve months. The rating comes as... Full story

Yahoo Finance • last month

Apellis signs royalty purchase deal with Sobi for Aspaveli

[Close up blood stream concept] J Studios Apellis Pharmaceuticals (NASDAQ:APLS [https://seekingalpha.com/symbol/APLS]) announced a new agreement with Sobi (SWOBF) (OTCPK:SWOBY [https://seekingalpha.com/symbol/SWOBY]) involving a capped ro... Full story

Yahoo Finance • 2 months ago

Apellis Pharma general counsel Watson sells $93k in stock

Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel David O. Watson sold 5,000 shares of common stock on June 16, 2025, at a price of $18.77, totaling $93,850. The sale comes amid a challenging period for the $2.23 billion market cap com... Full story

Yahoo Finance • 2 months ago

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observed New data presented at late-breaking session at the European Renal Association Congress Marke... Full story

Yahoo Finance • 3 months ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in... Full story

Yahoo Finance • 4 months ago

Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

We recently published a list of 11 Best Guru Stocks to Buy According to Wall Street Analysts. In this article, we are going to take a look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other Guru stocks to invest in.... Full story

Yahoo Finance • 4 months ago

Apellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

PDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority... Full story

Yahoo Finance • 5 months ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full year 2024 net product revenue... Full story

Yahoo Finance • 6 months ago

Apellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference

WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.... Full story

Yahoo Finance • 6 months ago

Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an indication extension applicati... Full story

Yahoo Finance • 6 months ago

Apellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

WALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024 financial results on... Full story

Yahoo Finance • 6 months ago

Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

SAN DIEGO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP, investigates potential violations of federal and state laws by certain officers of the companies of MacroGenics, Inc. (NASDAQ: MGNX), Apellis P... Full story